Intellia

Intellia
Focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Gene Editing
CRISPR Technology
Cell Engineering
Bioinformatics
Drug Development
Intellia在招职位
0个在招职位
目前没有在招职位
产品与服务
CR
CRISPR/Cas9 Gene Editing Platform
Gene Editing Technology
NT
NTLA-2001
Gene Editing Therapy
NT
NTLA-3001
Gene Editing Therapy
EX
Ex Vivo Cell Engineering
Cell Engineering Service
NT
NTLA-2002
Gene Editing Therapy
NE
Neurological Disease Programs
Gene Editing Therapy
PR
Primary Hyperoxaluria Program
Gene Editing Therapy
MO
Modular CRISPR Platform
Platform Technology
AS
ASGR1 Program
Gene Editing Therapy
IN
In Vivo Gene Editing Services
Gene Editing Service
LI
Lipid Nanoparticle Delivery System
Drug Delivery Technology

NTLA-5001
Cell Therapy
IM
Immunology Pipeline
Therapeutic Pipeline

NTLA-2003
Gene Editing Therapy

Asgard Platform
Platform Technology
LI
Lipid Nanoparticle Platform
Technology Platform
ON
Oncology Cell Therapies
Cell Therapy

Engineered Cell Medicines
Cell Therapy
CR
CRISPR Platform Technology
Technology Platform
相似公司

Moderna
mRNA medicines.
Cambridge, Massachusetts
1,001-5,000人
Public
估值 $47B

Pfizer
Breakthroughs that change patients' lives.
New York City, New York
10,001+人
Public
估值 $280B
499个在招职位

Biogen
Specializing in the treatment of neurological diseases.
Cambridge, Massachusetts
5,001-10,000人
Public
估值 $16.2B
347个在招职位

Bluebird Bio
Develops gene therapies for severe genetic disorders.
Somerville, Massachusetts
201-500人
Public
估值 $350M

Merck
Multinational pharmaceutical company.
Rahway, New Jersey
10,001+人
Public
估值 $208B
848个在招职位
最新动态
All
X
News
HN
YouTube
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
CRISPR Medicine News
News
·
1个月前
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
·
1个月前
·
1
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA) - TipRanks.com
Bull signal if I ever saw one
·
1个月前
·
89
·
34
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing - simplywall.st
simplywall.st
News
·
1个月前
Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture
·
1个月前
·
28
更多 (剩余15条)
浏览量
0
申请点击
0
Mock Apply
0
收藏
0
评价
2.7
2条评价
工作生活平衡
3.0
薪酬
3.0
企业文化
2.0
职业发展
2.5
管理层
1.5
25%
推荐率
优点
Potential for meaningful medical impact
Working on innovative treatments
Opportunity to help patients with rare diseases
缺点
Poor management decisions
Unfair layoff practices
Favoritism in promotions
薪资范围
47个数据点
Mid/L4
Mid/L4
1份报告
$214,500
年薪总额
基本工资
$165,000
股票
-
$214,500
$214,500
面试评价
1条评价
难度
3.0
/ 5
时长
2-5w
面试流程
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Offer
联系方式与地址